A Long Term Safety Study of Degarelix in Patients With Prostate Cancer
NCT00967018
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
77
Enrollment
INDUSTRY
Sponsor class
Conditions
Prostate Cancer
Interventions
DRUG:
Degarelix
Sponsor
Ferring Pharmaceuticals